Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B. Johnson, Justin M. Balko, Mellissa J. Nixon et al.|JCI Insight|2018Cited by 162
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Clinical Cancer Research|2021Cited by 26
MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.Justin M. Balko, Randall S. Davis, Douglas B. Johnson et al.|Journal of Clinical Oncology|2018Cited by 9
Abstract 853: Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patientsJennifer Bordeaux, Naveen Dakappagari, Douglas B. Johnson et al.|Cancer Research|2016Cited by 2
Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).Douglas B. Johnson, Jennifer Bordeaux, Ju‐Young Kim et al.|Journal of Clinical Oncology|2017Cited by 2